Comparative Pharmacology
Head-to-head clinical analysis: NORGESIC versus PARAFON FORTE DSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESIC versus PARAFON FORTE DSC.
NORGESIC vs PARAFON FORTE DSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NORGESIC is a combination of orphenadrine citrate, aspirin, and caffeine. Orphenadrine is a centrally acting muscle relaxant with anticholinergic properties; its exact mechanism is not fully understood, but it may act via central atropine-like effects and inhibition of reuptake of norepinephrine and serotonin. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, leading to analgesic, antipyretic, and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia via adenosine receptor antagonism.
Chlorzoxazone acts on the central nervous system (CNS) at the spinal cord level, possibly by depressing polysynaptic reflexes, producing skeletal muscle relaxation without affecting neuromuscular transmission.
1-2 tablets orally 2-4 times daily. Each tablet contains orphenadrine citrate 100 mg and acetaminophen 325 mg.
Adults: 4 g (500 mg x 8 tablets) orally every 6-8 hours as needed; maximum 8 g (16 tablets) per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 2–4 hours; clinical multiple dosing may require 4–6 hour intervals
1-3 hours (terminal); clinically relevant for dosing intervals of 4-6 hours.
Primarily renal (70% as unchanged drug and metabolites; 10% as unchanged) and biliary (30%)
Primarily renal (85-95% as glucuronide conjugates and unchanged drug; <5% fecal).
Category C
Category C
Muscle Relaxant
Muscle Relaxant/Analgesic Combination